Paradeep Phosphates Limited reported a 24% year-on-year increase in standalone net profit to ₹392.60 crore for the quarter ended June 30, 2026, driven by a 36% surge in revenue from operations to ₹6,124.25 crore. The strong financial performance was underpinned by a 4% growth in sales volume to 9.85 lakh metric tons (LMT) and improved EBITDA of ₹764 crore, up 24% year-on-year. EBITDA margin for the quarter stood at 11.76%, compared to 12.89% in the corresponding period of the previous year, reflecting proportional scaling of costs alongside robust top-line growth.

The Board of Directors approved the unaudited standalone and consolidated financial results on July 28, 2026. The results were reviewed by B S R & Co. LLP, the statutory auditors, who issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. In the same meeting, the Board approved a capital expenditure proposal of ₹250 crore to set up an Aluminium Fluoride (AlF3) plant at Paradeep, marking a strategic entry into industrial chemicals.

Financial Performance Highlights

Revenue from operations increased by ₹1,620.75 crore compared to the corresponding quarter of the previous year. Total income stood at ₹6,145.82 crore for Q1FY27, up from ₹4,537.55 crore in Q1FY26. Consolidated figures mirrored standalone numbers due to the group structure. The company recognized an exceptional item of ₹21.80 crore related to the reassessment of gratuity and leave liabilities following the notification of four Labour Codes by the Government of India.

*Figures derived from percentage change provided in source where absolute prior values were not explicitly restated in the new data but implied by YoY metrics.

Strategic Investments and Operational Updates

Managing Director and CEO N. Suresh Krishnan attributed the robust performance to efficient plant operations and competitive sourcing of key raw materials despite Middle East conflicts causing price volatility. He confirmed that the Phos Acid expansion project (Phase 1), increasing capacity from 500,000 MTPA to 700,000 MTPA at Paradeep, remains on track.

The newly approved ₹250 crore Aluminium Fluoride plant aims to diversify the company's portfolio into non-subsidy industrial chemicals. This investment leverages by-products to create value-added products, reinforcing manufacturing excellence. The amalgamation with Mangalore Chemicals & Fertilizers Limited (MCFL), effective from April 1, 2024, continues to drive scale, with financial results restated retrospectively to include MCFL operations.

What the Numbers Show

The divergence between the 36% revenue growth and the EBITDA margin compression — from 12.89% to 11.76% year-on-year — indicates that while top-line expansion is robust, cost structures are scaling proportionally. However, the stable employee benefits expense of ₹87.21 crore against significant revenue jumps indicates operational leverage in human capital costs. The decision to invest ₹250 crore in Aluminium Fluoride signals a strategic pivot towards diversifying away from subsidy-dependent fertilizer revenues, potentially improving long-term margin stability despite current global uncertainties.

The Board of Directors of Paradeep Phosphates Limited approved the introduction of the 'Paradeep Phosphates Limited Performance Stock Option Plan 2026' (PSOP 2026) during a meeting held on July 28, 2026. The proposal, recommended by the Nomination and Remuneration Committee, aims to align employee incentives with organizational growth by granting stock options to eligible personnel. The scheme is subject to final approval by the company's shareholders.

The approval was made pursuant to Regulation 30 read with Para B of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). The details were disclosed to the National Stock Exchange of India Limited and BSE Limited in accordance with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The Board meeting commenced at 2:00 P.M. (IST) and concluded at 5:00 P.M. (IST).

Plan Structure and Eligibility

The PSOP 2026 covers a total of 20,00,000 (Twenty Lakhs) stock options, which are exercisable into not more than 20,00,000 Equity Shares. Each share has a face value of ₹10/- (Rupee Ten Only) and is fully paid-up. The scheme is administered by the Committee authorized by the Board, which will determine eligibility based on roles that have a high impact on the organization's growth phase.

Pricing and Vesting Terms

The exercise price for the options shall be the face value of the equity shares on the date of grant, or as decided by the Committee under the Companies Act and SEBI (SBEB and SE) Regulations. In no case will the exercise price be lower than the face value of the equity shares on the date of grant. Different exercise prices may apply to different sets of employees for options granted on the same or different dates.

Vesting terms stipulate a minimum period of one year between the grant and vesting of options. The maximum vesting period may extend up to three years, or such other period as decided by the Committee. Vesting may occur in one or more tranches. Once vested, the options must be exercised within a period not exceeding two years from the date of respective vesting.

Administrative Framework

The PSOP 2026 will be implemented by the Board of Directors or the Compensation/Nomination & Remuneration Committee in compliance with the Companies Act, 2013, and applicable laws. All questions regarding the interpretation of the plan will be determined by the Board or the Committee, and such determinations will be final and binding upon all interested parties. The diluted earnings per share will be determined upon the exercise of these options.